AAAAAA

   
Results: 1-25 |
Results: 25
Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone
Authors: Chatzistamou, I Schally, AV Varga, JL Groot, K Busto, R Armatis, P Halmos, G
Citation: I. Chatzistamou et al., Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone, ANTI-CANC D, 12(9), 2001, pp. 761-768
Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix
Authors: Chatzistamou, I Schally, AV Szepeshazi, K Groot, K Hebert, F Arencibia, JM
Citation: I. Chatzistamou et al., Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix, CANCER LETT, 171(1), 2001, pp. 37-45
Gene targeting of envoplakin, a cytoskeletal linker protein and precursor of the epidermal cornified envelope
Authors: Maatta, A DiColandrea, T Groot, K Watt, FM
Citation: A. Maatta et al., Gene targeting of envoplakin, a cytoskeletal linker protein and precursor of the epidermal cornified envelope, MOL CELL B, 21(20), 2001, pp. 7047-7053
Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways
Authors: Rekasi, Z Varga, JL Schally, AV Plonowski, A Halmos, G Csernus, B Armatis, P Groot, K
Citation: Z. Rekasi et al., Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways, PEPTIDES, 22(6), 2001, pp. 879-886
Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide
Authors: Chatzistamou, I Schally, AV Varga, JL Groot, K Armatis, P Bajo, AM
Citation: I. Chatzistamou et al., Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide, J CANC RES, 127(11), 2001, pp. 645-652
Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cellline xenografted into nude mice
Authors: Chatzistamou, I Schally, AV Varga, JL Groot, K Armatis, P Busto, R Halmos, G
Citation: I. Chatzistamou et al., Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cellline xenografted into nude mice, J CLIN END, 86(5), 2001, pp. 2144-2152
Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth
Authors: Szepeshazi, K Schally, AV Armatis, P Groot, K Hebert, F Feil, A Varga, JL Halmos, G
Citation: K. Szepeshazi et al., Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth, ENDOCRINOL, 142(10), 2001, pp. 4371-4378
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours
Authors: Szepeshazi, K Schally, AV Groot, K Armatis, P Hebert, F Halmos, G
Citation: K. Szepeshazi et al., Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours, EUR J CANC, 36(1), 2000, pp. 128-136
Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways
Authors: Plonowski, A Schally, AV Varga, JL Rekasi, Z Hebert, F Halmos, G Groot, K
Citation: A. Plonowski et al., Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways, PROSTATE, 44(2), 2000, pp. 172-180
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice
Authors: Kahan, Z Nagy, A Schally, AV Halmos, G Arencibia, JM Groot, K
Citation: Z. Kahan et al., Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice, BREAST CANC, 59(3), 2000, pp. 255-262
Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro
Authors: Rekasi, Z Varga, JL Schally, AV Halmos, G Groot, K Czompoly, T
Citation: Z. Rekasi et al., Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro, P NAS US, 97(3), 2000, pp. 1218-1223
In vivo inhibition of PC-3 human androgen-independent prostate cancer by atargeted cytotoxic bombesin analogue, AN-215
Authors: Plonowski, A Nagy, A Schally, AV Sun, BD Groot, K Halmos, G
Citation: A. Plonowski et al., In vivo inhibition of PC-3 human androgen-independent prostate cancer by atargeted cytotoxic bombesin analogue, AN-215, INT J CANC, 88(4), 2000, pp. 652-657
Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: Evidence from in vitro studies on human prostatic and pancreatic cancer
Authors: Rekasi, Z Varga, JL Schally, AV Halmos, G Armatis, P Groot, K Czompoly, T
Citation: Z. Rekasi et al., Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: Evidence from in vitro studies on human prostatic and pancreatic cancer, ENDOCRINOL, 141(6), 2000, pp. 2120-2128
Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II
Authors: Kahan, Z Sun, BD Schally, AV Arencibia, JM Cai, RZ Groot, K Halmos, G
Citation: Z. Kahan et al., Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II, CANCER, 88(6), 2000, pp. 1384-1392
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers
Authors: Szepeshazi, K Schally, AV Groot, K Armatis, P Halmos, G Hebert, F Szende, B Varga, JL Zarandi, M
Citation: K. Szepeshazi et al., Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers, BR J CANC, 82(10), 2000, pp. 1724-1731
Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide
Authors: Kiaris, H Schally, AV Sun, B Armatis, P Groot, K
Citation: H. Kiaris et al., Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide, ONCOGENE, 18(50), 1999, pp. 7168-7173
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice
Authors: Koppan, M Nagy, A Schally, AV Plonowski, A Halmos, G Arencibia, JM Groot, K
Citation: M. Koppan et al., Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice, PROSTATE, 38(2), 1999, pp. 151-158
Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro
Authors: Csernus, V Schally, AV Groot, K
Citation: V. Csernus et al., Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro, PEPTIDES, 20(7), 1999, pp. 843-850
Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs
Authors: Szepeshazi, K Halmos, G Schally, AV Arencibia, JM Groot, K Vadillo-Buenfil, M Rodriguez-Martin, E
Citation: K. Szepeshazi et al., Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs, J CANC RES, 125(8-9), 1999, pp. 444-452
Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma
Authors: Kiaris, H Schally, AV Varga, JL Groot, K Armatis, P
Citation: H. Kiaris et al., Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma, P NAS US, 96(26), 1999, pp. 14894-14898
Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities
Authors: Varga, JL Schally, AV Csernus, VJ Zarandi, M Halmos, G Groot, K Rekasi, Z
Citation: Jl. Varga et al., Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities, P NAS US, 96(2), 1999, pp. 692-697
Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro
Authors: Csernus, V Schally, AV Groot, K
Citation: V. Csernus et al., Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro, J ENDOCR, 163(2), 1999, pp. 269-280
Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers
Authors: Kahan, Z Arencibia, JM Csernus, VJ Groot, K Kineman, RD Robinson, WR Schally, AV
Citation: Z. Kahan et al., Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers, J CLIN END, 84(2), 1999, pp. 582-589
Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238
Authors: Kahan, Z Nagy, A Schally, AV Hebert, F Sun, B Groot, K Halmos, C
Citation: Z. Kahan et al., Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238, INT J CANC, 82(4), 1999, pp. 592-598
Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207
Authors: Kahan, Z Nagy, A Schally, AV Halmos, G Arencibia, JM Groot, K
Citation: Z. Kahan et al., Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207, CANCER, 85(12), 1999, pp. 2608-2615
Risultati: 1-25 |